0.97
+0.03(+3.19%)
Currency In USD
| Previous Close | 0.94 |
| Open | 0.9 |
| Day High | 1 |
| Day Low | 0.92 |
| 52-Week High | 7.5 |
| 52-Week Low | 0.79 |
| Volume | 602,355 |
| Average Volume | 6.14M |
| Market Cap | 7.22M |
| PE | -0.09 |
| EPS | -10.6 |
| Moving Average 50 Days | 1.23 |
| Moving Average 200 Days | 2.7 |
| Change | 0.03 |
If you invested $1000 in Pasithea Therapeutics Corp. (KTTA) since IPO date, it would be worth $13.62 as of June 01, 2025 at a share price of $0.97. Whereas If you bought $1000 worth of Pasithea Therapeutics Corp. (KTTA) shares 3 years ago, it would be worth $50 as of June 01, 2025 at a share price of $0.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
GlobeNewswire Inc.
May 20, 2025 11:01 AM GMT
-- Demonstrates PAS-004’s potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
GlobeNewswire Inc.
May 14, 2025 11:02 AM GMT
-- First patient expected to be dosed during Q2 2025 ---- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous neurofibromas ---- Starting dose of 4mg tab
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
GlobeNewswire Inc.
May 07, 2025 9:00 PM GMT
Additional Gross Proceeds of Approximately $1.3 Million Received Upon Exercise of Certain Warrants Issued in the Public OfferingMIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. (“Pasithea,” or the “Company”) (Nasdaq: KTTA; KTTAW